What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His main research concerns Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Surgery.
His Internal medicine and Hazard ratio, Everolimus, Chemotherapy, Interim analysis and Neoadjuvant therapy investigations all form part of his Internal medicine research activities.
He interconnects Cancer, Docetaxel, Clinical endpoint, Clinical trial and Trastuzumab in the investigation of issues within Oncology.
His study in Breast cancer is interdisciplinary in nature, drawing from both Progression-free survival, Capecitabine and Phases of clinical research.
His Metastatic breast cancer research is multidisciplinary, incorporating elements of Prospective cohort study, Metastasis, Germline mutation and Carcinoembryonic antigen.
His Surgery study combines topics from a wide range of disciplines, such as Antiestrogen, Tamoxifen, Advanced Solid Tumor and Urology.
His most cited work include:
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer (2615 citations)
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer (1957 citations)
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer (997 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer.
His research on Internal medicine frequently connects to adjacent areas such as Surgery.
His research integrates issues of Letrozole, Clinical endpoint, Regimen and Docetaxel in his study of Oncology.
He has included themes like Adverse effect, Gynecology, Pathology and Hazard ratio in his Breast cancer study.
His Cancer research incorporates elements of Placebo and Cancer research.
His Metastatic breast cancer research incorporates themes from Taxane, Anthracycline, Gastroenterology, Capecitabine and Pharmacology.
He most often published in these fields:
- Internal medicine (76.03%)
- Oncology (67.46%)
- Breast cancer (44.92%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (76.03%)
- Oncology (67.46%)
- Breast cancer (44.92%)
In recent papers he was focusing on the following fields of study:
Mario Campone spends much of his time researching Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer.
Internal medicine is a component of his Chemotherapy, Letrozole, Trastuzumab, Cohort and Adverse effect studies.
His Oncology study also includes
- Adjuvant most often made with reference to Early breast cancer,
- Docetaxel which is related to area like Epirubicin.
His research investigates the link between Breast cancer and topics such as Hazard ratio that cross with problems in Survival rate.
His work deals with themes such as Placebo and Cancer research, which intersect with Cancer.
His Metastatic breast cancer research is multidisciplinary, incorporating perspectives in Taxane, Clinical trial, Overall survival, Metastasis and Estrogen receptor.
Between 2017 and 2021, his most popular works were:
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer (528 citations)
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. (198 citations)
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. (187 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
The scientist’s investigation covers issues in Internal medicine, Breast cancer, Oncology, Cancer and Metastatic breast cancer.
As part of the same scientific family, Mario Campone usually focuses on Internal medicine, concentrating on Placebo and intersecting with Letrozole.
His work deals with themes such as Concomitant, Clinical endpoint, Everolimus and Cohort, which intersect with Breast cancer.
The Oncology study combines topics in areas such as Carboplatin and Neutropenia, Chemotherapy.
His work in the fields of Cancer, such as Hormone receptor and Advanced breast, intersects with other areas such as Stage and Set.
In his work, Capecitabine is strongly intertwined with Tolerability, which is a subfield of Metastatic breast cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
